earma annual conference 23 june 2011 - magali poinot (part 1)
DESCRIPTION
Presentation lined up to EARMA annual Conference in Bragança - PortugalTRANSCRIPT
The writing and implementation of the Innovative Medicines Initiative projects
Part I
Elisabetta VaudanoPrincipal Scientific Manager
EARMA Annual Meeting23rd June 2011
What is IMI ?
An European Public-Private Partnership Focused on
Needs Common toPharmaceutical Industry and Patients
EARMA Annual Meeting23rd June 2011
3
The History of IMI2000: Lisbon Strategy wants to make Europe most
competitive and dynamic knowledge-based economy by 2010
2004: Industry-led European Technology Platforms (ETPs) develop Strategic Research Agendas addressing bottlenecks to competitiveness
2007: 7th Framework Programme for Research establishes the European Research Council and Joint Technology Initiatives
2008: Establishment of the Joint Undertakings to implement the Joint Technology Initiatives
2009: Appointment Executive Director & Autonomy IMI JU EARMA Annual Meeting
23rd June 2011
Governance
EARMA Annual Meeting23rd June 2011
IMI Executive Office as a Neutral Third-Party
• To implement programmes and activities in the common interest of all stakeholders
• To monitor the combined use of public funds and industry investment
• To guarantee fair and reasonable conditions for optimal knowledge exploitation and dissemination
EARMA Annual Meeting23rd June 2011
Source: Burrill & Company; US Food and Drug Administration.
Why IMI? The Productivity Gap in Pharma R&D
0
10
20
30
40
50
60
0
5
10
15
20
25
30
35
40
45
50
$55
New
Dru
g A
pp
rova
ls
Ph
arm
a R
&D
($ b
illi
on
s)
92 93 94 95 96 97 98 99 00 01 02 03 04 05 06 07
…M&A Impact on R&D Innovation
Munos B., Nature Reviews Drug Discovery 8, 959-968 (December 2009)
1+1=1Big is not Beautiful
EARMA Annual Meeting23rd June 2011
Why IMI? Society and Patients Need Innovative Treatments
Alzheimer’s Drugs: Summary of Recommendations
The medicines used to slow mental decline in people with Alzheimer's disease are not particularly effective. When compared with a placebo, only 10 to 20 percent more people taking an Alzheimer's drug seem to benefit at all. And it is the rare person who has a significant delay in the worsening of their symptoms over time.
However, there is no way as yet to predict who will respond and who will get little or no benefit from one of the five drugs approved to treat Alzheimer's disease. Thus, the decision to try one is a gamble and judgment is based on whether the treatment is worth the cost and the risk of side effects.
EARMA Annual Meeting23rd June 2011
IMI Objectives
• Making the pharmaceutical R&D process faster and more effective, rather than directly delivering new drugs
• Accelerating the development of safer and more effective medicines for patients in Europe
• Improving the environment for pharmaceutical R&D in Europe
• Boosting the biopharmaceutical sector in Europe
EARMA Annual Meeting23rd June 2011
Page 502
Collaborative Innovation to Deliver Innovative Medicines
Clinical pharmacology & Therapeutics | VOLUME 87 NUMBER 5 | MAY 2010
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Precompetitive Research to Boost Innovation in Biomedicine
EARMA Annual Meeting23rd June 2011
IMI Supports Precompetitive Research
IMI
EARMA Annual Meeting23rd June 2011
2 Billion Euro
1 Billion €1 Billion €
Public PrivatePartnership
Innovative Medicines Initiative:the Largest PPP in Life Sciences R&D
EARMA Annual Meeting23rd June 2011
EMA Supports IMI Research
EARMA Annual Meeting23rd June 2011
N ENGL J MED 362: 865-869, March 11, 2010
Patients are Active IMI Stakeholders
EARMA Annual Meeting23rd June 2011
The Four Pillars of the original IMI Strategic Research Agenda
EARMA Annual Meeting23rd June 2011
EARMA Annual Meeting23rd June 201117
IMI Projects Overview Call 1 &2
Call 1 Call 2 TotalProjects 15 8 23
EFPIA Companies 21 21 23
Academic teams 195 103 298SME teams 24 23 47
Patients’ organisat. 9 2 11
Total Budget (M€) 281 172 453
Call 1 Call 2 TotalProjects 15 8 23
EFPIA Companies 21 21 23
Academic teams 195 103 298SME teams 24 23 47
Patients’ organisat. 9 2 11
Total Budget (M€) 281 172 453
EFPIA Member Companies
Participating companies (Q2 2011):
EARMA Annual Meeting23rd June 2011
NEWMEDS
19
Develops biomarkers and tools and models to allow better targeted
treatments for schizophrenia and depression
19 Partners – 9 EFPIA companies
– 7 Public organisations
– 3 SMEs
Has assembled the largest known repository of antipsychotic clinical trail data. The database contains information on 23 401 patients from 67 industry sponsored studies. Bringing together data from public projects and 3 companies on the genetics
and clinical response in 1800 well characterized patients with depression.
Nature, 11 November 2010First achievements
EARMA Annual Meeting23rd June 2011
20
U-BIOPRED By comparing data from several hundreds of people, the team will characterise different kinds of severe asthma, paving the way towards a new classification of asthma and personalised treatments for patients
19 Partners - 8 EFPIA companies - 7 Academic Institutions - 3 Patients’ organizations
Thorax, in press
First achievements Consensus statement on the definition of severe refractory asthma
EARMA Annual Meeting23rd June 2011
21
eTOX Builds a large searchable database containing drug toxicity-related data extracted from relevant pharmaceutical pre-clinical legacy reportsDevelops innovative methodological strategies and novel software tools to better predict in silico the toxicological profiles of new molecular entities in early stages of the drug development pipeline, using its database background
25 Partners– 13 EFPIA companies– 8 Public organisations– 4 SMEs
An innovative multi-scale modelling strategy for the prediction of cardiotoxicity has been developed, successfully tested and published
First achievements
J. Chem. Inf. Model. 2011; 51:483-92
EARMA Annual Meeting23rd June 2011
22
SAFE-T Addresses the current lack of sensitive and specific clinical tests to diagnose and monitor drug-induced injury to the kidney, liver and vascular tissues in man, which is a major hurdle in drug development
20 Partners- 11 EFPIA Pharma Companies- 5 Academic Institutions- 4 SMEs
First achievements
153 potential biomarker candidates for drug-induced injury of the kidney, liver and vascular system have been evaluated and are currently undergoing clinical evaluation. The strategy adopted has been agreed with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Drug Discov Today, in press
EARMA Annual Meeting23rd June 2011
IMI Education and Training Projects
EARMA Annual Meeting23rd June 2011
The IMI Scientific Research Agendais under Revision
EARMA Annual Meeting23rd June 2011
The Pharmaceutical Industry is under pressure
The Product replacement Ratio is the ratio of revenue from new products (that is, those launchedin the previous 5 years) to the revenue lost from declining products.A ratio of less than 1reflects a failure to replace former successful products with new revenue drivers.
Harrison C., Nature Reviews Drug Discovery 10, 12-13 (January 2011)
EARMA Annual Meeting23rd June 2011
The Health-care Ecosystem is Changing….
• Health care reform and health IT, are driving the system to include many companies not traditionally involved in the health care business.
• Patients from been traditionally relatively passive participants in health delivery are been empowered by technological progress to become educated super-consumers with a much more active role in management of their health care.
EARMA Annual Meeting23rd June 2011
Pharma
Patients
Academia Physicians
BiotechsInsurers
Digital healthcare
Governments
CROs
MedTech
Social media
Regulators
The New Environment of “Big Pharma”
EARMA Annual Meeting23rd June 2011
Idea generationBasic researchand non-clinical
testingHuman testing
Marketeddrug
Regulatory approval
and Health technology assessment
Make Drug R&D processes in Europe more efficient and effective and enhance Europe’s competitiveness in the Pharma sector
Primary focus ofearly IMI calls
Primary focus ifwe want to make EU competitive
The Focus of IMI Research has to Become Broader
EARMA Annual Meeting23rd June 2011
Step 2:Consortia eligible for EU fundingcompete through expressions of interestwhich are ranked by independent experts
Step 1:A set of EFPIA companiesdefine a topic on which they commit to collaborate
Acad 1 Acad 2 Acad 3
Acad 4Patients’Organ 1
Regul 1
Patients’Organ 2
Other*
SME 1 SME 2
Pharma 1
Pharma 5
Pharma 2
Pharma 3Pharma 4
Pharma 6
Pharma 1
Pharma 5
Pharma 2
Pharma 3Pharma 4
Pharma 6
Acad 1 Acad 2 Acad 3
Acad 4Patients’Organ 1
Regul 1
Patients’Organ 2
Other*
SME 1 SME 2
Step 3:The top-ranked EU-fundable consortium join the EFPIAcompanies to form thefinal consortium which developsthe full proposal, subject to peer-review before final approval
Building a IMI Consortium
30
Key Concepts
• Open collaboration in final consortia
• Non-competitive research for EFPIA companies
• Competitive calls for IMI JU beneficiaries
EARMA Annual Meeting23rd June 2011
31
Building a IMI Project (1) IMI Research Agenda
(multi-annual plan)
Annual Scientific Priorities
Definition of research topics
Detailed description of research topics
Launch of the Call
Call definition and launch
• Contains EFPIA priorities • Advice of Scientific Committee (SC)• Consultation of States Representatives Group (SRG)• Approval by IMI Governing Board
• Proposed by EFPIA• Consultation of SC and SRG• Approval by IMI Governing Board
• Proposed by EFPIA
• EFPIA + IMI Executive Office• Consultation of SC and SRG• Approval by IMI Governing Board
•IMI Executive Office
EARMA Annual Meeting23rd June 2011
32
Building a IMI Project (2)
Submission of Expressions of Interest
First Peer review
First ranked consortium
Invitation to submitFull Project Proposal
Competition between
applicants’ consortia
(potential IMI JU beneficiaries)
• By applicants’ consortia (academics, SMEs, Patient org….)
• Independ. experts + EFPIA coordin.
• Independ. experts
• Approved by IMI Governing Board
• to first ranked applicants’ consortium + EFPIA consortium
assessment
ranking
EARMA Annual Meeting23rd June 2011
33
Building a IMI Project (3)
Submission of Full Project Proposal
Second Peer review(including ethics)
Approval of Full ProjectProposal
Joint Preparation of
Full ProjectProposal
• By full project consortium (first ranked applicants’ consortium + EFPIA consortium)
• Independent experts
• by IMI Governing Board
EARMA Annual Meeting23rd June 2011
34
Building a IMI Project (4)
assessment
ranking
Preparation of
Approval ofProject budget
Signature of Project Agreement
Contract negotiation
• by full project consortium + IMI JU Executive Office
• by IMI Governing Board
• by full project consortium
Grant agreement
Project agreement • by full project consortium
Signature of Grant Agreement
• by full project consortium + IMI JU Executive Office
EARMA Annual Meeting23rd June 2011
35
CALL 4 TOPICS (1)
Cluster A: Medical Information System• A European medical information framework (EMIF) of
patient-level data to support a wide range of medical research
• eTriks: European translational information and knowledge management services
Cluster B: Chemistry, Manufacturing and Control• Delivery and targeting mechanisms for biological
macromolecules• In vivo predictive biopharmaceuticals tools for oral
drug delivery• Sustainable chemistry – Delivering medicines for the
21st centuryEARMA Annual Meeting
23rd June 2011
36
CALL 4 TOPICS (2)
Cluster C: Technology and Molecular Disease Understanding
• Human induced pluripotent stem (hiPS) cells for drug discovery and safety assessment
• Understanding and optimising binding kinetics in drug discovery
Indicative total financial contribution from IMI JUfor the 7 full projects Up to 105 M€
EARMA Annual Meeting23rd June 2011
37
CALL 4 TIMELINE • Open Info Day: 17 June 2011
• Official Launch: End June 2011
• Deadline submission of Expression of Interests: End October 2011
• Peer-review Evaluation: November 2011
• Deadline submission Full Project Proposals: March 2012
• Approval of Full Project Proposals: May 2012
EARMA Annual Meeting23rd June 2011
THANK YOU !
www.imi.europa.eu
EARMA Annual Meeting23rd June 2011